Track HHI movement year on year. Lock in long-term agreements on consolidating lanes; renegotiate pricing where competition is opening up.
The enzalutamide India to Turkey lane consolidated from HHI 0.32 (competitive) to HHI 0.99 (near-monopoly) across a single year. Six exporters held the lane in both years; the value moved overwhelmingly toward one. The shift is the metric: a stable lane just flipped category, and the DOJ horizontal-merger threshold (0.40) was crossed in the same window.
A single lane to compare year over year, or a basket of molecules to scan for the largest shifts in either direction.
Lane HHI in the latest full year against the prior year. Exporter count, top-3 share, and lane value deltas surface alongside the HHI shift.
Citation-anchored brief categorising the lane as consolidating (lock in supply) or opening up (renegotiate pricing). Handoff to procurement strategy.
Consolidating lanes are lock-in candidates: sign before the supplier raises. Opening lanes are renegotiation candidates: drop your price.
Lanes that moved more than 3000 HHI points in either direction get surfaced. Tune the threshold to your tolerance.
An HHI 8000 lane that has been HHI 8000 for three years is steady-state. An HHI 8000 lane that was HHI 3000 last year is a different story. The delta is the signal.
If HHI rose without exporter count falling, the structure changed because one exporter took share. If exporter count fell too, a player exited. Different playbooks.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve molecule-lanes from the live warehouse with the largest absolute HHI delta · arrow direction implied by the second-year value · 0 to 1 scale.
The lane-dynamics view is the time-derivative on the HHI signal. PharmaDB compares year-over-year HHI per lane, categorises each as consolidating or opening up, and surfaces the largest movers in either direction. The view is lane_competitiveness (two-year join); the source table is molecule_country_flow.
A change of 3000 HHI points in either direction year on year. The default surface threshold; tune lower if you want a wider list. Lanes inside the noise band are not flagged.
Consolidating lanes are lock-in candidates. Sign a long-term agreement with the leader before pricing reflects the new structure. Opening lanes are renegotiation candidates. Bring fresh exporters into the RFQ and drop your spend.
The trade data shows the shape: HHI 3150 to 9867 with the exporter count flat at six. One leader took dominant share. The cause is often a single-supplier capacity win or a regulatory cycle. The local-market knowledge fills in the why.
Yes. A lane can consolidate while shrinking. Both signals surface independently. Cold-corridor detection covers volume collapse; this page covers structural concentration.
Trade aggregates refresh weekly. The two-year delta recomputes on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Yes. Pass a destination filter (US, EU, BR, ZA, AE, TR) and the AI agent returns only lanes ending in that market. Useful for country managers who run a single-market portfolio.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.